Medinol Strikes Twice: Guidant Entanglement May Affect Boston Scientific
This article was originally published in The Gray Sheet
Executive Summary
Medinol is seeking royalties of at least 20% from past and future sales of Guidant's Multi-Link stent platform in an upcoming patent infringement trial that could begin by April
You may also be interested in...
Medinol v. Guidant patent trial
July 10 trial date set for the U.S. District Court for the Southern District of New York to assess the validity of Medinol's '381 patent related to the flexibility of its coronary stents. If Medinol's claims hold, the jury will set damages based on Guidant's infringement of the Israeli firm's patent. Medinol was granted summary judgment on Feb. 10 that Guidant violated its patent (1"The Gray Sheet" March 6, 2006, p. 4). Once started, the trial is expected to conclude within seven trial days. The Israeli firm is asking for royalties of at least 20% from past and future sales of Guidant's Multi-Link stent platform...
Medinol v. Guidant patent trial
July 10 trial date set for the U.S. District Court for the Southern District of New York to assess the validity of Medinol's '381 patent related to the flexibility of its coronary stents. If Medinol's claims hold, the jury will set damages based on Guidant's infringement of the Israeli firm's patent. Medinol was granted summary judgment on Feb. 10 that Guidant violated its patent (1"The Gray Sheet" March 6, 2006, p. 4). Once started, the trial is expected to conclude within seven trial days. The Israeli firm is asking for royalties of at least 20% from past and future sales of Guidant's Multi-Link stent platform...
Abbott Hits The Jackpot With Boston Scientific’s Acquisition Of Guidant
Abbott stands poised to become a vascular and endovascular powerhouse should Boston Scientific's acquisition of Guidant clear Federal Trade Commission antitrust hurdles